Jasper Therapeutics : Corporate Presentation May 2024

Jasper Therapeutics

Corporate Presentation

May 2024

Safe Harbor Statements

Forward-Looking Statements

This investor presentation and any accompanying oral presentation (together, this "Presentation") contain forward-looking statements. All statements other than statements of historical fact contained in this Presentation, including statements regarding the future opportunities and prospects of Jasper Therapeutics, Inc. (together with its subsidiary, "Jasper" or the "Company"), including milestones, potential regulatory filings and the anticipated timing thereof, patient enrollment, future timelines, business strategy, and plans and objectives for future operations, are forward-looking statements. Jasper has based these forward-looking statements on its estimates and assumptions and its current expectations and projections about future events. These forward- looking statements are subject to a number of risks, uncertainties and assumptions, including those contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2023, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that the Company has subsequently filed or may subsequently file with the SEC. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Presentation are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Jasper undertakes no obligation to update publicly or revise any forward-looking statements for any reason after the date of this Presentation or to conform these statements to actual results or to changes in Jasper's expectations.

Industry and Market Data

Certain data in this Presentation was obtained from various external sources, and neither the Company nor its affiliates, advisers or representatives has verified such data with independent sources. Accordingly, neither the Company nor any of its affiliates, advisers or representatives makes any representations as to the accuracy or completeness of that data or undertakes any obligation to update such data after the date of this Presentation. Such data involves risks and uncertainties and is subject to change based on various factors.

Trademarks

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of the Company.

Briquilimab is an investigative
drug and is not approved
for any indication	2

Briquilimab: Franchise Potential in Mast Cell Diseases

c-Kit inhibition	•	c-Kit inhibition is the only therapeutic mechanism shown to significantly deplete mast cells
clinically validated	•	Mast cell depletion has unique potential to deliver safe and durable disease control
MOA in mast cell	•	c-Kit inhibition has demonstrated clinical proof of concept in multiple mast cell mediated diseases
	diseases

	Briquilimab	• Briquilimab is a potent c-Kit inhibitor proven to drive mast cell depletion
	•	Briquilimab could allow for less frequent dosing
a	potent c-Kit
	inhibitor	•	Optimal biologic dosing and PK profile could minimize unwanted adverse effects

	Robust pipeline	• CSU: Enrolling patients in Phase 1b/2a BEACON study (initial data expected 3Q 2024)
	•	CIndU: Enrolling patients in Phase 1b/2a SPOTLIGHT study (initial data expected 2H 2024)
	multiple company-
	led clinical	•	Asthma: Enrollment in Phase 1b/2a study expected to commence Q4 2024
	programs	•	Additional mast cell mediated indications under evaluation

NON-CONFIDENTIAL

Briquilimab is an investigative
drug and is not approved
for any indication	3

Investigator Sponsored Studies

Expanded portfolio presents exciting new opportunities in mast cell diseases

Indication

Sponsor

Preclinical

Phase 1

Phase 2

Phase 3

Program Milestones

Briquilimab

Mast Cell Diseases (Subcutaneous)

		•	Phase 1b/2a being conducted in the US and EU
Chronic Spontaneous Urticaria	BEACON	•	Actively enrolling patients
		•	Initial clinical data expected in 3Q 2024
		•	Phase 1b/2a study being conducted in the EU
Chronic Inducible Urticaria	SPOTLIGHT	•	Actively enrolling patients
		•	Initial clinical data expected in 2H 2024
Asthma		• Enrollment in Phase 1b/2a expected Q4 2024
	•	Initial clinical data expected 2H 2025

Stem Cell Diseases (Intravenous)

Low-to-Intermediate Risk MDS

SCID

Fanconi Anemia

SCD / CGD / GATA2 MDS

• Enrolling patients
• Initial clinical data expected mid-year 2024
• Enrolling patients
• Discussing potential BLA filing with the FDA
• First 6 patients achieved full chimerism & count recovery; expansion to Phase 2a (enrolling)
• First 3 patients with full chimerism & Hb increase (SCD)
• Enrolling patients (CGD
• Study start up (GATA2 MDS)

Jasper maintains full worldwide rights to develop and commercialize briquilimab in all indications

Briquilimab is an investigative
drug and is not approved
for any indication	4

Mast cells are the most potent drivers of inflammatory response in skin, lungs and gut

• Skin mast cells are primitive immune cells involved in protection against venom and parasitic infection

• Mast cells triggered by allergens, viruses and other irritants degranulate and release pro-inflammatory compounds implicated in large number of immunologic diseases

• Limited function or need for skin mast cells in modern settings

Metz et al. Allergy (2023)

Briquilimab is an investigative
drug and is not approved
for any indication	5

Mast cells are key drivers of the inflammatory response in a number of immunologic diseases with high unmet need

• Activated mast cells are the perpetrating cell driving diseases such as:

•	Asthma	•	Eosinophilic Esophagitis
•	Atopic Dermatitis		(EoE)
•	Chronic Rhinosinusitis	•	Prurigo Nodularis
•	COPD	•	Urticaria

• Currently approved therapies targeting mast cell driven diseases rely on indirect mast inhibition and have limited efficacy and durability of response

	Briquilimab is an investigative
	drug and is not approved
Theoharides et al. N Engl J Med. (2015)	for any indication	6

Depletion of mast cells by anti-c-Kit monoclonal antibody blockade is a novel approach with potential to deliver safe and durable disease control

• Briquilimab is an aglycosylated IgG1 anti c-Kit antibody with high affinity to c-Kit
• • Aglycosylated c-Kit antibodies avoid indiscriminate ADCC driven killing of other c-Kit expressing cells1
  • Kd < 5pM affinity to human c-Kit with IC50 ~ 70pM
  • Human mast cell survival bioassay IC50 ~12.5nM
  • Half life of 9 days
• Briquilimab blocks c-Kit signaling at the SCF ligand binding site on the receptor triggering apoptosis
• • Mast cell depletion occurs within hours to days
• Mast cell recovery in the skin takes 3 months or longer2, potentially leading to durable disease control

Briquilimab	Stem Cell Factor (SCF)

MC

ckit

P13KApoptosis

MC

MC

AKTBIM

FOXO3A

MC

MC Apoptosis

APOPTOTIC MC

Programmed Cell Death

Apoptotic MC

Apoptotic MC

Durable

Depletion

Apoptotic MC

1.	Arnold JN et al. Annu Rev Immunol (2007)	Briquilimab is an investigative
drug and is not approved
2.	Maurer et al, GA²LEN Global Urticaria Forum - Berlin, December 6, 2022
for any indication	7

Mast cell depletion may lead to deeper and more durable efficacy compared to inhibition and silencing approaches

Pathways Contributing to Mast Cell Activation

IgE
FcεRI
	BTK
MRGPRX2	Mast Cell

Siglec-6

IL-13Rα1

IL-4Rα

Pathways Regulating Mast Cell Survival

Mast Cell Survival

c-Kit

SCF

Blockade of c-Kit signaling on mast cells leads to apoptosis via the BIM-mediated pathway and phagocytic clearance

Briquilimab is an investigative
drug and is not approved
for any indication	8

Single administration of anti-c-Kit antibody leads to rapid and durable depletion of skin mast cells

• Significant depletion of mast cells occurs within one week following dosing
• Serum tryptase reduction correlates to mast cell depletion
• Serum tryptase recovery precedes return of urticarial symptoms and skin mast cells

Single Dose of Barzolvolimab in CIndU (3 mg/kg IV)

	14		Skin Mast Cells
of view	12		Tryptase+
10
		CD117+
8
MC/field	6
4
2
	0
	0	6	12	18	24	30	36
				Week

• Following depletion, mast cell	Minimal recovery of skin mast cells by week 36 following single
administration of barzolvolimab IV in CIndU patients1
recovery in the skin takes at
least three months1

	Briquilimab is an investigative
	drug and is not approved
1 Maurer et al, GA²LEN Global Urticaria Forum - Berlin, December 6, 2022	for any indication	9

Briquilimab significantly depletes skin mast cells in humans at doses above ~0.8 mg/kg

• A single subcutaneous dose at or above ~80mg potently depletes mast cells in the skin of healthy volunteers
• Cmax reached at ~day 5
• Depletion begins occurring as early 7 days following dosing
• Robust depletion at day 29
• Briquilimab's favorable pharmacokinetic properties may enable optimal biologic dosing

Skin mast cell depletion 4 weeks after single dose (≥42 mg)1

Briquilimab Healthy Volunteer Phase 1 Subcutaneous Study

Briquilimab dose (mg)

1 Jasper internal data (Phase 1a, healthy volunteer study); Dose is adjusted to body weight (mg/kg) on graph. Skin biopsies were used to count mast cells.	Briquilimab is an investigative
drug and is not approved
	for any indication	10